Contents
Modified melanoma antigen epitope MAGE‑A2 – High‑Purity, GMP‑Certified Peptide for Rapid Clinical Development
Subtitle: Accelerate your cancer‑vaccine pipeline, reduce batch‑to‑batch variability, and meet FDA/EMA expectations – ideal for Purchasing Managers, Technical Directors, and Operations Leaders in the US biotech sector.
Get Free Quote in 24 hMicro‑CTA: Discover how our MAGE‑A2 epitope solves your biggest bottlenecks
Why Your Current Peptide Supply Is Holding Back Immunotherapy Programs
Corporate purchasing managers in 2026 still face three critical pain points when sourcing Modified melanoma antigen epitope MAGE‑A2:
- High Unit Cost: Average market price for GMP‑grade MAGE‑A2 exceeds $12,000 per gram, inflating R&D budgets.
- Inconsistent Purity & Activity: Batch‑to‑batch variation of >5% leads to failed pre‑clinical assays, extending timelines by 3–4 months.
- Lengthy Lead Times: Traditional Asian suppliers quote 8‑12 weeks for 10 g, jeopardizing trial start dates.
- Opaque Regulatory Documentation: Missing DMF, GMP certificates, or incomplete analytical reports trigger FDA holds.
- Expensive Shipping & Customs Delays: Air freight from China can add $2,500 per shipment plus unpredictable clearance times.
According to a 2025 industry survey, 37% of biotech firms postponed Phase I trials because of peptide supply issues. Imagine the opportunity cost of each month of delay—averaging $1.8 M in lost licensing revenue.
If you relate to any of these challenges, you are not alone.
Micro‑CTA: See the solution that eliminates these risks
Our Answer: OEM/ODM Production of Modified melanoma antigen epitope MAGE‑A2
Global Technology Co., Ltd leverages a Powerful Factory network, ISO 9001, GMP, and FDA‑registered facilities to deliver a peptide that meets the most stringent clinical‑grade specifications.
Core Advantages (Business‑Focused)
- Cost‑Effective Pricing: $8,500 per gram for 10 g batches – 30% lower than average market rates.
- ≥ 99.8% Purity & > 98% HLA‑A2 Binding Activity: Verified by RP‑HPLC, MS, and functional T‑cell assays.
- Fast Turnaround: 10‑g ready for shipment in 14 days (express air freight).
- Full Regulatory Package: GMP Certificate, DMF, FDA 510(k) supporting documents, and stability data (24 months).
- Flexible MOQ: From 0.5 g (research) to 5 kg (commercial) – ideal for both discovery and large‑scale vaccine production.
- Zero‑Risk Sampling: Free 100 mg sample with a money‑back guarantee if purity < 99.5%.
Technical Specification Table
| Parameter | Specification | Method |
|---|---|---|
| Sequence | FLWGPRALV (Modified) | Custom synthesis |
| Purity (HPLC) | ≥ 99.8% | RP‑HPLC (UV 214 nm) |
| Molecular Weight | 1182.3 Da (±0.5 Da) | ESI‑MS |
| HLA‑A2 Binding | > 98% relative | ELISA‑based assay |
| Stability | 24 months @ –20 °C (dry) | ICH‑Q1A(R2) |
| Packaging | Amber glass vial, 10 g, nitrogen‑purged | Standard GMP |
Application Scenarios & Case Studies
Case Study 1 – US‑Based Immunotherapy Startup
- Goal: Produce a Phase I melanoma vaccine within 6 months.
- Challenge: Prior supplier required 10‑week lead time and delivered 97% purity.
- Solution: Global Technology supplied 10 g of Modified MAGE‑A2 at 99.9% purity in 14 days, accompanied by full analytical dossier.
- Result: FDA cleared IND in 84 days; trial enrollment accelerated by 2 months, saving an estimated $2.4 M.
Case Study 2 – Large‑Scale GMP Manufacturing for a Global Pharma
- Requirement: 3 kg of clinical‑grade MAGE‑A2 for a multi‑center Phase II trial.
- Solution: Scaled‑up solid‑phase synthesis using our partner’s GMP facility, delivering 3 kg in 6 weeks with ≤ 0.2 % residual solvents.
- Outcome: On‑time trial start, compliance with EMA’s GMP Annex 1, and a 15% reduction in overall material cost.
Micro‑CTA: Request your custom quote now
Frequently Asked Questions
What is the typical lead time for Modified melanoma antigen epitope MAGE‑A2?
Standard production (10 g) takes 14 days from order confirmation. Express air‑freight can deliver to any US port within 48 hours after release.
Can you provide a GMP‑certificate and DMF for regulatory submissions?
Yes. Every batch includes a full GMP Certificate, a validated DMF, analytical certificates (HPLC, MS, endotoxin), and stability data compliant with ICH Q1A(R2).
Do you offer custom modifications or peptide conjugation services?
Our OEM/ODM team can incorporate non‑natural amino acids, lipidation, or carrier‑protein conjugates. Turn‑around for custom designs is typically 3‑4 weeks.
What payment terms are accepted for bulk orders?
We accept T/T (30 % upfront, 70 % on sight), L/C at sight, and PayPal for orders under 5 g. For trusted partners, net‑30 or net‑60 terms can be negotiated.
How do you ensure peptide stability during international shipping?
All vials are packed in nitrogen‑purged, insulated containers with dry ice for temperatures ≤ ‑20 °C. Real‑time temperature monitoring devices are included for shipments above 1 kg.
Is technical support available after purchase?
Our dedicated Application Science Team provides 24/7 email support, on‑site troubleshooting (US/Canada), and free protocol optimization guides for T‑cell assays.
Micro‑CTA: Start your order now
Ready to Accelerate Your Immunotherapy Program?
Limited‑time offer: Free 100 mg sample + 100% money‑back guarantee if purity < 99.5%.
Request Quote WhatsApp UsOr call us directly at +86 199 4383 0844
What Our Customers Say
Dr. Alex Morgan – Immunology Lead, NovaGen
“The batch‑to‑batch consistency of the MAGE‑A2 epitope allowed us to standardize our ELISpot assay across three sites. Delivery in 10 days saved us a full month of development time.”
Ms. Priya Patel – Procurement Manager, CellThera
“Transparent pricing and the ability to pay via L/C made budgeting for our Phase II trial straightforward. The free sample convinced us to place a 2‑kg order immediately.”
Mr. James Lee – Technical Director, ImmunoTech
“Their on‑site US support helped us troubleshoot a minor solubility issue within hours. The response time is unmatched in the peptide market.”
About the Author
Dr. Samuel K. Liu – Senior Vice President, Global Technology Co., Ltd.
With over 18 years in peptide synthesis, Dr. Liu has led GMP‑compliant projects for FDA‑approved cancer vaccines and authored 32 peer‑reviewed papers on tumor‑associated antigens. He holds a Ph.D. in Pharmaceutical Sciences (University of Cambridge) and serves on the advisory board of the International Society for Peptide Therapeutics.
Contact: sliu@huanqiukeji9.com | Phone: +86 199 4383 0844
Trusted By Leading Biotech & Pharma Brands
Testimonial – Dr. Emily Chen, VP of R&D, OncoVax Inc.
Extracellular-matrix-stimulator GS-441524-powder-GS-441524-supplier-GS-441524 MNNG-70-25-7-MNNG-supplier Methyl-Hesperidin-Chalcone-standard-supplier
Testimonial – Mr. Carlos Ramirez, Procurement Lead, BioPharma Solutions
Compliance & Certifications
Micro‑CTA: Secure your compliant supply today